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Abstract
Background: Patients with type 2 diabetes mellitus (T2D) are prone to micro- and macro-vascular complications.
Monomeric and oligomeric flavanols (MOF) isolated from grape seeds (Vitis vinifera) have been linked to improved
endothelial function and vascular health. The aim of this study is to determine the effect of a daily supplementation
of 200 mg MOF on renal endothelial function of patients with T2D and microalbuminuria.
Methods/design: For this double-blind, placebo-controlled, randomized, multicenter trial 96 individuals (ages 40–
85 years) with T2D and microalbuminuria will be recruited. Participants will be randomly assigned to the intervention
group, receiving 200 mg of MOF daily for 3 months, or to the control group, receiving a placebo. The primary
endpoint is the evolution over time in albumin excretion rate (AER) until 3 months of intervention as compared with
placebo. Secondary endpoints are the evolution over time in established plasma markers of renal endothelial
function—asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble
intercellular cell adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), and von Willebrand Factor (vWF)—until 3 months
of intervention as compared with placebo. Mixed modeling will be applied for the statistical analysis of the data.
Discussion: We hypothesize that T2D patients with microalbuminuria have a medically determined requirement for
MOF and that fulfilling this requirement will result in a decrease in AER and related endothelial biomarkers. If
confirmed, this may lead to new insights in the dietary management of patients with T2D.
Trial registration: Nederlands Trial Register, NTR4669, registered on 7 July 2014.
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Background
Diabetes has become a worldwide epidemic. The esti-
mated global prevalence of diabetes for adults between 20
and 79 years of age was 8.8% in 2017. This prevalence is
expected to increase to 9.9% in 2045. About 4.0 million
people between 20 and 79 years of age died from diabetes
in 2017, resulting in a global all-cause mortality of 10.7%
for people in this group [1, 2]. Patients with type 2 dia-
betes (T2D) are prone to develop micro- and
macro-vascular complications [2, 3], reducing quality of
life and putting a heavy burden on the health-care system
[4]. At diagnosis, 6.5% of patients with T2D already show
microalbuminuria; of these, 2.8% yearly progress into
macroalbuminuria and 2.3% into nephropathy [5]. Micro-
albuminuria is a good proxy of endothelial dysfunction in
patients with T2D and is strongly associated with an un-
favorable cardiovascular and renal outcome [6]. Other
established biomarkers for endothelial function are asym-
metric dimethylarginine (ADMA), soluble vascular cell
adhesion molecule 1 (sVCAM-1), interleukin-6 (IL-6), von
Willebrand Factor (vWF), and soluble intercellular cell ad-
hesion molecule 1 (sICAM-1), all of which have been re-
lated to renal endothelial health and vascular
complications in T2D [7].
Monomeric and oligomeric flavanols and their
physiological effect
A recent publication of the ADVANCE (Action in Dia-
betes and Vascular Disease: Preterax and Diamicron
Modified-Release Controlled Evaluation) trial showed that
moderate consumption of alcohol, particularly wine, was
associated with reduced cardiovascular events, micro-
vascular complications, and all-cause mortality in patients
with T2D [8]. Over the past decades, researchers have
wondered which compounds of wine could be responsible
for the lower risk of cardiovascular disease. Lately, the no-
tion that the presence of monomeric and oligomeric flava-
nols (MOF) could explain the cardio-protective effects of
red wine has found broad acceptance [9]. In the human
diet, a broad variety of single and condensed forms of
MOF, ranging from monomers (catechins) and oligomers
(oligomeric proanthocyanidins, or OPCs) to polymers, is
found in red wine, tea, cacao, legumes, and bark, peels,
and skins of many plants [10]. In a report in 2012, the
European Food Safety Authority (EFSA) acknowledged
that cacao flavanols maintain endothelium-dependent
vasodilation [11]. However, the MOF level in the average
Western diet tends to be low [12].
In a prospective cohort study (European Prospective In-
vestigation into Cancer and Nutrition, or EPIC), a signifi-
cant inverse trend was observed between MOF intake and
risk of T2D [13]. Another trial showed a significant associ-
ation between the intake of polyphenols, of which MOF
are a subclass, and a decreased risk of cardiovascular
disease (CVD) [14]. Higher intakes of anthocyanins (red
pigments of which condensed flavanols are the precursors)
and flavones (a class of flavonoids) have been associated
with significant improvements in insulin sensitivity and
high-sensitivity C-reactive protein (hs-CRP) levels [15].
Grape seed extracts containing relevant concentrations of
MOF significantly decreased systolic blood pressure and
CRP level in patients with T2D [16]. A daily supplementa-
tion of 150 mg of MOF significantly reduced several
microvascular abnormalities in patients with diabetic ne-
phropathy and retinopathy [17, 18]. In a recent study, use
of 200 mg MOF per day for 8 weeks resulted in vascular
health benefits in “healthy” male smokers [19]. In the
same study, MOF modulated the expression of genes as-
sociated with cardiovascular disease pathways, mainly
genes involved in chemotaxis, cell adhesion, cell infiltra-
tion, and cytoskeleton organization, suggesting diminished
immune cell adhesion to endothelial cells [20]. Whether
MOF have a physiological effect on the renal endothelial
health of patients with T2D has not yet been established.
Objective
The objective of this study is to assess the effects of daily
supplementation of 200 mg MOF on renal endothelial
function in T2D patients with microalbuminuria.
Methods/design
Study design
This study is a double-blind, randomized, controlled,
multicenter trial. After giving written informed consent,
eligible participants will be randomly assigned to placebo
or intervention for 3 months. Outcome parameters will
be measured at baseline, at 6 weeks, and at 3 months. In
Fig. 1, we show the flow chart of this study. The SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) checklist for study protocols is provided
as an Additional file 1.
Study population
Patients with T2D will be recruited from the diabetes out-
patient clinic of the Erasmus Medical Center in Rotterdam
and the community hospitals of Havenziekenhuis, IJsselland
Ziekenhuis and Ikazia Ziekenhuis as well as GP-clinic
Stichting Gezond op Zuid in Rotterdam. Patients who at-
tend the diabetes outpatient clinics of the participating cen-
ters will be screened for eligibility through assessing their
medical records by the study coordinator (MR). Then eli-
gible patients are informed by their designated physician
about the trial during a routine control appointment. If the
patients are interested, the study coordinator provides them
with a flyer and additional information at the outpatient
clinic. Hereafter, patients will be given at least 2 weeks to
decide whether they want to participate. Inclusion is
complete after signing the informed consent form.
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Definition of T2D
Information on the diagnosis of T2D was obtained from
patient’s medical records. Diabetes was defined accord-
ing to the World Health Organization [21] and the
American Diabetes Association [22] guidelines as at least
one of the following:
 Fasting plasma glucose of at least 7.0 mmol/L,
measured at at least two separate time points
 Non-fasting plasma glucose level of at
least 11.1 mmol/L, measured at at least two separate
time points
 HbA1c of at least 48 mmol/mol, measured at at least
two separate time points
 Using anti-diabetic medication
 Diagnosis of T2D documented in the patient’s
medical record by the designated physician.
The information was checked by the study coordin-
ator. In case of uncertainty, the patient’s treating phys-
ician was consulted.
Inclusion criteria
 T2D, as defined in the section above
 Age of 40–85 years
 Microalbuminuria in the previous 6 months (as
microalbuminuria can change during time, results
should not be older than 6 months), defined as one
of the following:
 30–300 mg albumin in a 24-h urine sample
 or 3.5–35 mg albumin/mmol creatinine in females
and 2.5–25 mg albumin/mmol creatinine in males in
a urine portion.
Assessment of eligibility based on inclusion and exclusion criteria
Multicenter recruitment in 1 academic center, 3 community hospitals and 1 
GP clinic in Rotterdam, The Netherlands
Written informed consent
Baseline measurements 
Randomization 1:1
No informed consent
Measurements after 6 
weeks
200 mg MOF once daily for 3 
months
Placebo once daily for 3 months
Measurements after 3 
months
Not eligible
Fig. 1 Flow chart of the study
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This definition is derived from the Dutch national
guidelines [23].
Exclusion criteria
 Other types of diabetes mellitus as derived from the
medical records
 Prior (less than 4 weeks before participating) or
current use of any specific dietary supplementary
products providing daily amounts of MOF of 25 mg/
day or higher
 Anticoagulation medication
 Major health conditions: organ transplantation,
untreated cancer, current chemotherapy or
radiotherapy, or acute or chronic organ failure
 Microalbuminuria due to conditions other than T2D
 Pregnancy or lactation during the trial.
Randomization and blinding
Patients will be randomly assigned to either intervention
or control group at an allocation ratio of 1:1. All investi-
gators, medical staff, statisticians, and participants are
blinded to the intervention. The statistician generates
the allocation sequence and delivers it to the nutritional
company responsible for the preparation of the product
and placebo. The nutritional company produces the re-
search product and placebo using the same packages
without labels of the company or product name. We do
not mention the product or company’s name to the par-
ticipants. The sachets are packaged in boxes containing
the appropriate amount for a 3-month intervention of
an individual subject. The boxes are labeled with a
unique numerical code, derived from the generated allo-
cation sequence. They will be given to the participants
in consecutive order. To avoid bias, the consecutive
order of the labeled boxes is strictly followed. Thus, the
first recruited patient is handed box number 1, the sec-
ond patient is handed box number 2, and so on, regard-
less of the center of recruitment. Furthermore, the
nutritional company prepares two identical sealed boxes,
each containing 114 numerical coded envelopes with the
respective treatment allocation inside. One sealed box
will be stored at a secured place where only the principal
investigator has direct access; the other sealed box will
be kept at a secured place at the office of the head of the
department. Only in case of a medical urgency is the
blinding code to be broken. The designated physician
and the principal investigator are ultimately responsible
for the final decision of breaking the code for a single
subject. Otherwise, decoding will first take place after a
blind review including preliminary statistical analyses of
the primary outcome data by an independent statistician.
In all cases, unblinding will take place in the presence of
a witness.
Sample size calculation
Considering a clinically relevant effect of 20% change of
albumin excretion rate (AER), which is half the effect of
angiotensin-converting enzyme inhibitors (ACEis) on
AER [24, 25], we estimated that the average AER of 100
decreased to 80 μg/min albumin (standard deviation 40)
in the intervention group compared with no expected
change in the placebo group. With a two-sided alpha set
at 0.05 and power at 0.80 and a correlation of 0.70 be-
tween the three repeated measures, we calculated that at
least 48 patients in each study group (i.e. 96 in total)
would be required [26].
Intervention and control
Research product, treatment, and placebo Masque-
lier’s® Endoclair® (abbreviated as MOF) was designed as
Food for Special Medical Purpose by I.N.C. Agency B.V.
(Loosdrecht, The Netherlands) in accordance with EU
Commission Directive 1999/21/EC of 25 March 1999 on
dietary foods for special medical purposes. Its active in-
gredient is 200 mg of catechins and epi-catechins (single
flavan-3-ols) and oligomeric flavan-3-ol units (dimers to
pentamers) per sachet. The MOF have been extracted
from Vitis vinifera (grape seeds). Detailed analyses have
established that the preparation is standardized to con-
tain about 85% (wt/wt) flavan-3-ols (as established with
the vanillin-H2SO4 assay [27]), of which 50% to 60% (wt/
wt) are single and dimeric flavan-3-ols (determined by
high-performance liquid chromatography), and poly-
meric proanthocyanidins (hexamers and beyond) are
below detection limit. The manufacturer guarantees the
stability of the product composition until the expiration
date. For the manufacturing of the placebo, only the ac-
tive ingredient (MOF) is removed from the product.
Product and placebo will be from the same batch. The
placebo product has the same package, taste, and color
as the research product (Table 1). When the white pow-
der is dissolved in water, a similar yellowish solution is
obtained with both preparations.
In the composition of both the investigational prod-
uct and the placebo, 150 mg of black tea extract
(BTE) is included for taste and color reasons only
(Table 1). The amount of the total polyphenols in the
BTE is about 30 mg, the same amount as in one cup
of tea. This amount is the same for the placebo and
the investigational product and thus does not influ-
ence our results.
In its quality control process, the manufacturer uses
“Complex Phytonutrient Authentication” via nuclear
magnetic resonance and principal component analysis to
authenticate the quality and standardized amount of the
MOF fractions. For the exact content and nutritional
value per sachet, see Tables 1 and 2.
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The dose of MOF and the duration of the intervention
in the current trial were based on data from previous
prospective human studies, in which MOF amounts be-
tween 100 and 300 mg per day for durations from 15 to
90 days were used. In these studies, positive effects on
cardiovascular health without serious side effects were
observed [19, 20]. Therefore, a dosage of 200 mg and a
treatment duration of 3 months in the current study are
most likely sufficient in order to address the objective.
There is a hypothetical risk for patients using anticoagu-
lation medications: the product could have a mild and
dose-dependent platelet-inhibiting effect [28]. Therefore,
to avoid possible interactions, we decided to exclude all
patients using anticoagulants. As side effects, nausea and
epigastric discomfort when starting with the product
have been reported in a minority of patients. These side
effects are most likely caused by the used sweeteners
and therefore will be the same for both the control and
intervention groups. Side effects will be monitored dur-
ing the trial.
We instruct the patient to take the daily dosage at the
same time point each day, once a day, preferably half an
hour before a meal or in between meals. The product
should be dissolved in a glass of tap water at room
temperature and be drunk immediately. In case of gastro-
intestinal discomfort while using the product, splitting the
dosage might help lessen the discomfort. In that case, the
patient may split the daily dosage into two dosages. During
the 3-month study period, we will regularly contact partici-
pants by phone to encourage them to complete the study.
This will also be done face-to-face at the three measure-
ment moments. Compliance will be assessed by question-
naires in which participants are asked for the number of
sachets they forgot to use and for which reason.
Study procedure At baseline, 6 weeks, and 3 months,
24-h urine will be collected for AER measurements. Infor-
mation about demographic variables, lifestyle, adverse ef-
fects, compliance, and food intake will be collected by
using standard questionnaires. The urine collection pro-
cedure starts in the morning and lasts 24 h; it stops at the
same time point it started the day before. During collec-
tion, all of the produced urine is collected in a container
that was handed out to the patient at the outpatient clinic.
Within a couple of hours after the collection, urine is de-
livered in the outpatient clinic. AER is measured the same
day as soon as possible after delivery. The patient is
instructed to keep the container with urine in a dark and
cool place at room temperature until delivery. At baseline
and after 3 months, blood samples will be collected for de-
termination of ADMA, sVCAM-1, sICAM-1, IL-6, and
vWF and for measuring HbA1c fasting glucose, lipids, cre-
atinine, and estimated glomerular filtration rate (eGFR).
Non-fasted venous blood is collected in EDTA tubes at a
random moment of the day at the outpatient clinic.
Plasma samples will be stored at −80 °C until analysis. Al-
though patients are not required to fast before blood col-
lection, we do keep a record of whether they fasted or not.
In addition, body weight, blood pressure, and waist/hip
circumference will be measured. In Fig. 2, we show a
schedule of the study procedures. All participants receive
usual care as provided by their diabetes team and must
continue all of their prescribed medication, including ad-
justments when required. Since this may potentially affect
our outcome measures, all used medications, dosage mod-
ifications, and other medical interventions during the trial
will be recorded to adjust for this potentially confounding
effect. We will ask the participants to keep their current
lifestyle unchanged. There are no dietary restrictions dur-
ing the study, except for the use of specific dietary supple-
ment products containing at least 25 mg MOF. To
control for dietary flavanols in regular food, we will use
detailed dietary questionnaires to calculate the amounts.
Table 1 Ingredients of the placebo and the research product
Formulation placebo
Sweetener (isomalt GS-PF; E953) 1400 mg
Food acid (citric acid; E330) 200 mg
Black tea extract 150 mg
Natural lemon flavor 20 mg
Anti-caking agent (tricalcium phosphate) E341(iii)) 10 mg
Acidity regulator (tripotassium citrate))) E332(ii)) 10 mg
Sweetener (sucralose; E955) 10 mg
Total 1800 mg
Formulation Endoclair®
Sweetener (isomalt GS-PF; E953) 1400 mg
Monomeric and oligomeric flavanols 200 mg
Food acid (citric acid; E330) 200 mg
Black tea extract 150 mg
Natural lemon flavor 20 mg
Anti-caking agent (tricalcium phosphate) E341(iii)) 10 mg
Acidity regulator (tripotassium citrate) E332(ii)) 10 mg
Sweetener (sucralose; E955) 10 mg
Total 2000 mg
Table 2 Nutritional value per sachet of placebo and research
product
Energy 4.12 kcal
Fat 0.0 g
Carbohydrates 1.5 g (polyols)
Protein 0.0 g
Sodium 0.0 mg
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Outcome measures
Primary outcome measure The primary endpoint is
difference in evolution of AER from baseline to 3 months
of intervention in absolute values as compared with pla-
cebo. AER will be measured in a 24-h urine sample at
the clinical chemistry laboratory of the Erasmus Medical
Center. The albumin level in urine will be measured by
immunoturbidimetric assay (Roche Diagnostics GmbH,
Mannheim, Germany).
Secondary outcome measures The difference between
intervention and placebo in change of AER expressed as
percentage of baseline AER will be taken as a secondary
outcome. Other secondary endpoints are the differences
in the course of the established plasma markers of renal
endothelial function (ADMA, sVCAM-1, sICAM-1, IL-6,
and vWF) from baseline to 3 months. These markers will
be measured by using enzyme-linked immunosorbent
assays.
Other study parameters HbA1c, fasting glucose, lipids,
eGFR, and plasma creatinine will be measured at the
clinical chemistry laboratory of the Erasmus Medical
Center by using routine lab techniques.
Data monitoring All data will be filed and managed by
using the trial management system OpenClinica (Wal-
tham, MA, USA). Data will be entered into OpenClinica
with a consecutive code number (no initials or birth
date). Human material (blood samples) will also be
encoded and kept at −80 °C until analysis. The subject
identification code list, which links the code number to
the participant, will be safeguarded by the secretary of
STUDY PERIOD
Enrolment Allocation Post-allocation
TIMEPOINT T=-2 weeks T=0 T=0 T=6 weeks T=12 weeks
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Placebo daily
200 mg of MOF daily
ASSESSMENTS:
Demographic 
variables
X
Lifestyle/medication 
questionnaire
X X X
Adverse effects 
questionnaire
X X
Compliance 
questionnaire
X X
Food frequency 
questionnaire
X X X
AER in 24h urine 
sample
X X X
Routine lab 
measurements
X X
ADMA, sVCAM-1, 
sICAM-1, IL-6 and 
vWF
X X
Body weight 
X X
Blood pressure
X X
Waist circumference
X X
Fig. 2 Schedule of enrolment, interventions, and assessments. Abbreviation: SPIRIT Standard Protocol Items: Recommendations for Interventional Trials
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the department of internal medicine in a “master file”.
The key to the code is accessible by the investigators
only. Study data can be accessed only by the investigator
team, staff of the Health Care Inspection, and members
of the Medical Ethical Committee, as stated in the in-
formed consent form. The handling of personal data will
comply with the Dutch Personal Data Protection Act (in
Dutch: De Wet Bescherming Persoonsgegevens, WBP).
All data, urine, and blood samples will be kept for a
maximum of 15 years after the trial has finished.
An independent data monitoring committee (DMC) will
be established in accordance with research integrity guide-
lines of the Erasmus Medical Center. The current trial has
been identified as a trial with minimal risk for the partici-
pants and therefore the frequency of monitoring by the
DMC will be only once a year. During this monitoring
visit, the following items will be checked: the trial master
file, inclusion speed, informed consent (sample of 10% of
the participants), inclusion and exclusion criteria (sample
of 1–10%), compliance with the protocol (sample of 1–
10%), source document verification (sample of 1–10%),
(serious) adverse events (sample of 1–10%), instructions
of study procedures, certification of laboratories involved,
and the labeling and storage of biological samples.
Public disclosure and publication policy The results of
this trial will be disclosed unreservedly. We registered the
trial before its start in the Netherlands Trial Registry. Our
intention is to publish the results as soon as possible after
completion of the sample analyses and data evaluation in
an appropriate peer-reviewed scientific journal.
Safety In case of a suspected serious adverse event (SAE),
the investigator will report the SAE to the sponsor without
undue delay after obtaining knowledge of the event. Via
the web portal ToetsingOnline, the sponsor will report the
SAEs to the accredited METC (the medical research ethics
committee, which approved the protocol) within 7 days of
first knowledge for SAEs that result in death or are
life-threatening followed by a period of a maximum of
8 days to complete the initial preliminary report. All other
SAEs will be reported within a period of 15 days after the
sponsor has first knowledge of the SAEs. Because of the
low risk associated with the investigational product, no
data and safety monitoring board or safety committee will
be established.
Statistical analysis All analyses will be conducted in ac-
cordance with the intention-to-treat principle. We will
use the mean (in case of normal distribution) and me-
dian values (in case of non-normal distribution) as mea-
sures of central tendency for numerical data and the
standard deviation and interquartile range as measures
of variability, respectively. Mixed modeling will be
applied for longitudinal analyses of the data. Mixed
modeling can efficiently handle data with missing and
unbalanced time points. Three levels in the models will
be postulated. The participating centers constitute the
upper level, the patients the middle level, and their re-
peated measures the lower level. First, for each outcome
variable, a model will be postulated, and the primary or
secondary outcomes will be dependent variables. The
models will include treatment group, time, and loga-
rithm of time and treatment-time interactions as fixed
effects. The deviance statistic [29] using restricted max-
imum likelihood [30] will be applied to determine
whether the covariance structure should also include
slope and intercept-slope interaction next to the inter-
cept. No interim analysis will be performed. Analyses
will be carried out by using SPSS version 21.0 (IBM,
Armonk, NY, USA) (http://www-01.ibm.com/support/
docview.wss?uid=swg21608060).
Discussion
The presence of microalbuminuria is associated with
endothelial dysfunction and poor cardiovascular outcome in
T2D [31]. Although microalbuminuria is associated with a
number of other risk factors, it is considered an independ-
ent risk factor for CVD and cardiovascular events in
diabetes [31]. The exact mechanism leading from microal-
buminuria to end organ damage is not yet completely
understood. Endothelial dysfunction, however, might play a
crucial role in this process [32]. Hypothetically, microalbu-
minuria is a signal of endothelial dysfunction leading to in-
creased permeability of atherogenic lipoprotein particles
[31]. In addition to endothelial dysfunction, a number of
metabolic disorders are associated with microalbuminuria
leading to cardiovascular damage: transvascular leaking of
albumin in vessels, elevated glomerular filtration rate, ele-
vated blood pressure, hyperinsulinemia, elevated plasma fi-
brinogen levels, and altered blood lipid levels and function
may also play important roles [31, 32].
Treating microalbuminuria by improving endothelial
function is most probably beneficial in patients with T2D.
Although ACEis and angiotensin receptor inhibitors (angio-
tensin receptor blockers, or ARBs) are effective treatments
to achieve this goal [31, 32], use of MOF as part of the diet-
ary management may also be an effective auxiliary strategy.
The individual responses to ACEis and ARBs show large
variation. They are not equally effective in treating microal-
buminuria in each individual patient [32]. Besides, a re-
markable percentage of treated patients with T2D will
eventually develop diabetic kidney disease during the course
of the disease [33]. Therefore, if MOF are proven to fulfill
the specific nutrient requirement, they may become a diet-
ary tool to manage albumin excretion in patients with T2D
and microalbuminuria in general and in the insufficient re-
sponders to ACEis and ARBs in particular.
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Obviously, the safety features of MOF are very important.
In contrast to ACEis and ARBs, Endoclair MOF is registered
as a food supplement for special medical purposes, not re-
quiring patient monitoring upon first application. The ad-
vantageous effects of MOF on reversing endothelial
dysfunction and maintaining cardiovascular health have
been widely addressed in past decades; in epidemiological
studies, average dietary intake of flavanols has been linked
to health status [9, 13–16, 19, 20, 32, 34]. Nevertheless, there
is a lack of clinical and well-conducted studies specifically
addressing the effects of MOF on renal endothelial function
in T2D.
We hypothesize that the use of 200 mg MOF daily for
3 months will have a beneficial effect on renal endothelial
function and will result in a decrease of AER. This may lead
to new insights into the dietary management of T2D pa-
tients with renal complications. MOF could have beneficial
effects on endothelial function in other parts of the body as
well, as suggested by previous studies [9, 13–16, 19, 20, 32,
34]. Finally, since the participants in this trial are recruited
from tertiary, secondary, and primary referral centers, our
study sample well represents T2D patients with microalbu-
minuria in general.
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